Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $270

Benzinga Newsdesk www.benzinga.com Positive 90.6%

Neg 0% Neu 0% Pos 90.6%

Guggenheim analyst Vamil Divan maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $266 to $270.